
Voyager Therapeutics (VYGR) Stock Forecast & Price Target
Voyager Therapeutics (VYGR) Analyst Ratings
Bulls say
Voyager Therapeutics Inc. is positioned for a positive financial outlook due to its innovative TRACER platform, which is expected to generate revenue through collaborations advancing to clinical trials in the 2030s. The company has demonstrated promising preclinical results, including a substantial reduction in tau messenger RNA and protein levels in non-human primates, indicating potential efficacy and lower exposure levels compared to existing therapies. Additionally, comparisons of its non-viral NeuroShuttle's performance highlight key advantages in durability and safety, suggesting that Voyager’s approach may offer improved treatment outcomes for neurological diseases.
Bears say
Voyager Therapeutics Inc. has faced challenges in advancing its gene therapy pipeline, which includes notable programs such as Anti-tau Antibody (VY-TAU01) and SOD1 Silencing Gene Therapy. Recent financial reports indicate a significant increase in operating losses, raising concerns about the company's ability to sustain its research and development expenses without additional funding. Furthermore, delayed clinical trial progress and regulatory hurdles may impede Voyager's pathway to commercialization, contributing to a diminished outlook on its stock performance.
This aggregate rating is based on analysts' research of Voyager Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Voyager Therapeutics (VYGR) Analyst Forecast & Price Prediction
Start investing in Voyager Therapeutics (VYGR)
Order type
Buy in
Order amount
Est. shares
0 shares